Who is sponsoring NCT03042715?

NCT03042715 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT03042715?

Interventions in NCT03042715: Qualitative Interviews.

What condition does NCT03042715 study?

NCT03042715 studies Stem Cell Transplant Complications.

Is NCT03042715 still recruiting?

NCT03042715 is currently completed. Last updated 1 September 2021.

Are results published for NCT03042715?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-09-01 · How we verify

NCT03042715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psychological Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HCT)

Completed Results posted Last updated 1 September 2021

What this trial tests

trial testing Qualitative Interviews in Stem Cell Transplant Complications in 6 participants. Completed in 1 August 2017.

Timeline

6 March 2017

Primary endpoint
1 August 2017

1 August 2017

Quick facts

Lead sponsor	Massachusetts General Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6
Start date	6 March 2017
Primary completion	1 August 2017
Estimated completion	1 August 2017
Sites	1 location across United States

Drugs / interventions tested

Qualitative Interviews

Conditions studied

Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Pilot Qualitative Refinement of the Caregiver Intervention Primary · 1 year

qualitative data to develop and refine the caregiver intervention

intervention length is feasible

Group	Value	95% CI
Qualitative Refinement	5

session length is appropriate

Group	Value	95% CI
Qualitative Refinement	5

preferred fewer visits

Group	Value	95% CI
Qualitative Refinement	3

focus on mindfulness is appropriate

Group	Value	95% CI
Qualitative Refinement	5

Sponsor's own description

This research study is evaluating a psychological intervention for caregivers of patients undergoing stem cell transplantation. Phase 1 will include a qualitative phase to refine the intervention to specifically target the needs of caregivers Phase 2 of the trial will transition to an interventional randomization clinical trial

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Qualitative Interviews

Trials testing the same drug.

NCT06099691 — Outcomes That Matter and Questionnaires for Older People With Frailty · completed
NCT05571488 — Swiss Cohort of Health Professionals and Informal Caregivers · recruiting
NCT05482919 — The Adolescent Surgery Experience: A Mixed Methods Analysis · completed
NCT05061095 — Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey · completed
NCT05219149 — CNS Qualitative Interview · recruiting

Other recruiting trials for Stem Cell Transplant Complications

Currently open trials in the same condition.

NCT07509749 — Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) · Phase 2 · recruiting
NCT07340723 — Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) · Phase 2 · recruiting
NCT06541002 — A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors · NA · recruiting
NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
NCT06512545 — Modified Second Haplo-transplantation for Graft Failure · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03042715 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 1 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03042715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing